相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Study of mirtazapine for agitated behaviours in dementia (SYMBAD): a randomised, double-blind, placebo-controlled trial
Sube Banerjee et al.
LANCET (2021)
Agitation in Dementia: Real-World Impact and Burden on Patients and the Healthcare System
Eddie Jones et al.
JOURNAL OF ALZHEIMERS DISEASE (2021)
Healthcare utilization and monetary costs associated with agitation in UK care home residents with advanced dementia: a prospective cohort study
A. Buylova Gola et al.
INTERNATIONAL PSYCHOGERIATRICS (2020)
Time to invest in prevention and better care of behaviors and psychological symptoms associated with dementia
Claire V. Burley et al.
INTERNATIONAL PSYCHOGERIATRICS (2020)
Pharmacotherapy of Behavioral and Psychological Symptoms of Dementia: State of the Art and Future Progress
Radoslaw Magierski et al.
FRONTIERS IN PHARMACOLOGY (2020)
Healthcare resource utilisation and costs of agitation in people with dementia living in care homes in England - The Managing Agitation and Raising QUality of LifE in Dementia (MARQUE) study
Monica Panca et al.
PLOS ONE (2019)
Improving the quality of life of care home residents with dementia: Cost-effectiveness of an optimized intervention for residents with clinically significant agitation in dementia
Renee Romeo et al.
ALZHEIMERS & DEMENTIA (2019)
Clinical and cost-effectiveness of the Managing Agitation and Raising Quality of Life (MARQUE) intervention for agitation in people with dementia in care homes: a single-blind, cluster-randomised controlled trial
Gill Livingston et al.
LANCET PSYCHIATRY (2019)
Prevalence of and associations with agitation in residents with dementia living in care homes: MARQUE cross-sectional study
Gill Livingston et al.
BJPSYCH OPEN (2017)
Monetary costs of agitation in older adults with Alzheimer'sdisease in the UK: prospective cohort study
Stephen Morris et al.
BMJ OPEN (2015)
Agitation in cognitive disorders: International Psychogeriatric Association provisional consensus clinical and research definition
Jeffrey Cummings et al.
INTERNATIONAL PSYCHOGERIATRICS (2015)
Short- and Long-term Mortality Risk Associated with the Use of Antipsychotics Among 26,940 Dementia Outpatients: A Population-Based Study
Ellen Melbye Langballe et al.
AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY (2014)
START (STrAtegies for RelaTives) study: a pragmatic randomised controlled trial to determine the clinical effectiveness and cost-effectiveness of a manual-based coping strategy programme in promoting the mental health of carers of people with dementia
Gill Livingston et al.
HEALTH TECHNOLOGY ASSESSMENT (2014)
Effect of Citalopram on Agitation in Alzheimer Disease The CitAD Randomized Clinical Trial
Anton P. Porsteinsson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
The GERAS Study: A Prospective Observational Study of Costs and Resource Use in Community Dwellers with Alzheimer's Disease in Three European Countries - Study Design and Baseline Findings
Anders Wimo et al.
JOURNAL OF ALZHEIMERS DISEASE (2013)
Using Resource Use Logs to Reduce the Amount of Missing Data in Economic Evaluations Alongside Trials
Elsa Marques et al.
VALUE IN HEALTH (2013)
Efficacy of Memantine for Agitation in Alzheimer's Dementia: A Randomised Double-Blind Placebo Controlled Trial
Chris Fox et al.
PLOS ONE (2012)
Estimating Preference-Based Single Index Measures for Dementia Using DEMQOL and DEMQOL-Proxy
Donna Rowen et al.
VALUE IN HEALTH (2012)
Interim Scoring for the EQ-5D-5L: Mapping the EQ-5D-5L to EQ-5D-3L Value Sets
Ben van Hout et al.
VALUE IN HEALTH (2012)
Predictors of costs of care in Alzheimer's disease: A multinational sample of 1222 patients
Anders Gustavsson et al.
ALZHEIMERS & DEMENTIA (2011)
Donepezil for the treatment of agitation in Alzheimer's disease
Robert J. Howard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility
A Manca et al.
HEALTH ECONOMICS (2005)
分享论文
